| Year |
Citation |
Score |
| 2010 |
Cramer NP, Best TK, Stoffel M, Siarey RJ, Galdzicki Z. GABAB-GIRK2-mediated signaling in Down syndrome. Advances in Pharmacology (San Diego, Calif.). 58: 397-426. PMID 20655490 DOI: 10.1016/S1054-3589(10)58015-3 |
0.68 |
|
| 2009 |
Baek KH, Zaslavsky A, Lynch RC, Britt C, Okada Y, Siarey RJ, Lensch MW, Park IH, Yoon SS, Minami T, Korenberg JR, Folkman J, Daley GQ, Aird WC, Galdzicki Z, et al. Down's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1. Nature. 459: 1126-30. PMID 19458618 DOI: 10.1038/Nature08062 |
0.671 |
|
| 2008 |
Best TK, Cho-Clark M, Siarey RJ, Galdzicki Z. Speeding of miniature excitatory post-synaptic currents in Ts65Dn cultured hippocampal neurons. Neuroscience Letters. 438: 356-61. PMID 18490108 DOI: 10.1016/j.neulet.2008.04.039 |
0.711 |
|
| 2007 |
Olson LE, Roper RJ, Sengstaken CL, Peterson EA, Aquino V, Galdzicki Z, Siarey R, Pletnikov M, Moran TH, Reeves RH. Trisomy for the Down syndrome 'critical region' is necessary but not sufficient for brain phenotypes of trisomic mice. Human Molecular Genetics. 16: 774-82. PMID 17339268 DOI: 10.1093/Hmg/Ddm022 |
0.699 |
|
| 2007 |
Best TK, Siarey RJ, Galdzicki Z. Ts65Dn, a mouse model of Down syndrome, exhibits increased GABAB-induced potassium current. Journal of Neurophysiology. 97: 892-900. PMID 17093127 DOI: 10.1152/jn.00626.2006 |
0.704 |
|
| 2006 |
Siarey RJ, Kline-Burgess A, Cho M, Balbo A, Best TK, Harashima C, Klann E, Galdzicki Z. Altered signaling pathways underlying abnormal hippocampal synaptic plasticity in the Ts65Dn mouse model of Down syndrome. Journal of Neurochemistry. 98: 1266-77. PMID 16895585 DOI: 10.1111/J.1471-4159.2006.04238.X |
0.678 |
|
| 2006 |
Harashima C, Jacobowitz DM, Stoffel M, Chakrabarti L, Haydar TF, Siarey RJ, Galdzicki Z. Elevated expression of the G-protein-activated inwardly rectifying potassium channel 2 (GIRK2) in cerebellar unipolar brush cells of a Down syndrome mouse model. Cellular and Molecular Neurobiology. 26: 719-34. PMID 16783527 DOI: 10.1007/S10571-006-9066-4 |
0.7 |
|
| 2006 |
Harashima C, Jacobowitz DM, Witta J, Borke RC, Best TK, Siarey RJ, Galdzicki Z. Abnormal expression of the G-protein-activated inwardly rectifying potassium channel 2 (GIRK2) in hippocampus, frontal cortex, and substantia nigra of Ts65Dn mouse: a model of Down syndrome. The Journal of Comparative Neurology. 494: 815-33. PMID 16374808 DOI: 10.1002/Cne.20844 |
0.712 |
|
| 2005 |
Siarey RJ, Villar AJ, Epstein CJ, Galdzicki Z. Abnormal synaptic plasticity in the Ts1Cje segmental trisomy 16 mouse model of Down syndrome. Neuropharmacology. 49: 122-8. PMID 15992587 DOI: 10.1016/J.Neuropharm.2005.02.012 |
0.714 |
|
| 2003 |
Galdzicki Z, Siarey RJ. Understanding mental retardation in Down's syndrome using trisomy 16 mouse models. Genes, Brain, and Behavior. 2: 167-78. PMID 12931790 DOI: 10.1034/j.1601-183X.2003.00024.x |
0.717 |
|
| 2001 |
Galdzicki Z, Siarey R, Pearce R, Stoll J, Rapoport SI. On the cause of mental retardation in Down syndrome: extrapolation from full and segmental trisomy 16 mouse models. Brain Research. Brain Research Reviews. 35: 115-45. PMID 11336779 DOI: 10.1016/S0926-6410(00)00074-4 |
0.733 |
|
| 2001 |
Klein RC, Siarey RJ, Caruso A, Rapoport SI, Castellino FJ, Galdzicki Z. Increased expression of NR2A subunit does not alter NMDA-evoked responses in cultured fetal trisomy 16 mouse hippocampal neurons. Journal of Neurochemistry. 76: 1663-9. PMID 11259484 DOI: 10.1046/J.1471-4159.2001.00170.X |
0.679 |
|
| 2000 |
Shetty HU, Siarey RJ, Galdzicki Z, Stoll J, Rapoport SI. Ts65Dn mouse, a Down syndrome model, exhibits elevated myo-inositol in selected brain regions and peripheral tissues. Neurochemical Research. 25: 431-5. PMID 10823574 DOI: 10.1023/A:1007592006005 |
0.667 |
|
| 1999 |
Siarey RJ, Carlson EJ, Epstein CJ, Balbo A, Rapoport SI, Galdzicki Z. Increased synaptic depression in the Ts65Dn mouse, a model for mental retardation in Down syndrome. Neuropharmacology. 38: 1917-20. PMID 10608287 DOI: 10.1016/S0028-3908(99)00083-0 |
0.687 |
|
| 1997 |
Siarey RJ, Stoll J, Rapoport SI, Galdzicki Z. Altered long-term potentiation in the young and old Ts65Dn mouse, a model for Down Syndrome. Neuropharmacology. 36: 1549-54. PMID 9517425 DOI: 10.1016/S0028-3908(97)00157-3 |
0.72 |
|
| 1997 |
Siarey RJ, Coan EJ, Rapoport SI, Galdzicki Z. Responses to NMDA in cultured hippocampal neurons from trisomy 16 embryonic mice. Neuroscience Letters. 232: 131-4. PMID 9310297 DOI: 10.1016/S0304-3940(97)00581-8 |
0.673 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 1995 |
Siarey RJ, Andreasen M, Lambert JD. Serotoninergic modulation of excitability in area CA1 of the in vitro rat hippocampus. Neuroscience Letters. 199: 211-4. PMID 8577400 DOI: 10.1016/0304-3940(95)12063-A |
0.216 |
|
| 1990 |
Long SK, Smith DA, Siarey RJ, Evans RH. Effect of 6-cyano-2,3-dihydroxy-7-nitro-quinoxaline (CNQX) on dorsal root-, NMDA-, kainate- and quisqualate-mediated depolarization of rat motoneurones in vitro. British Journal of Pharmacology. 100: 850-4. PMID 1976402 DOI: 10.1111/j.1476-5381.1990.tb14103.x |
0.19 |
|
| 1991 |
Siarey RJ, Long SK, Evans RH. Potentiation of synaptic reflexes by D-serine in the rat spinal cord in vitro. European Journal of Pharmacology. 195: 241-4. PMID 1678709 DOI: 10.1016/0014-2999(91)90541-W |
0.184 |
|
| 1992 |
Siarey RJ, Long SK, Evans RH. The effect of centrally acting myorelaxants on NMDA receptor-mediated synaptic transmission in the immature rat spinal cord in vitro. British Journal of Pharmacology. 107: 628-33. PMID 1330190 |
0.181 |
|
| 1990 |
Siarey RJ, Long SK, Evans RH. Potentiation of spinal synaptic transmission in vitro by D-serine in the presence of CNQX European Journal of Pharmacology. 183: 1667. DOI: 10.1016/0014-2999(90)91960-J |
0.177 |
|
| 1994 |
Siarey RJ, Long SK, Tulp MT, Evans RH. The effects of central myorelaxants on synaptically-evoked primary afferent depolarization in the immature rat spinal cord in vitro. British Journal of Pharmacology. 111: 497-502. PMID 7911716 |
0.149 |
|
| 1990 |
Dolin SJ, Patch TL, Rabbani M, Siarey RJ, Bowhay AR, Little HJ. Nitrendipine decreases benzodiazepine withdrawal seizures but not the development of benzodiazepine tolerance or withdrawal signs. British Journal of Pharmacology. 101: 691-7. PMID 1963805 |
0.114 |
|
| 1991 |
Whittington MA, Dolin SJ, Patch TL, Siarey RJ, Butterworth AR, Little HJ. Chronic dihydropyridine treatment can reverse the behavioural consequences of and prevent adaptations to, chronic ethanol treatment. British Journal of Pharmacology. 103: 1669-76. PMID 1834295 DOI: 10.1111/J.1476-5381.1991.Tb09845.X |
0.112 |
|
| 1991 |
Siarey RJ, Long SK, Evans RH. Effect of clonidine on synaptic activity of rat in vitro spinal cord preparations Journal of Physiology. 435: 70P. |
0.11 |
|
| 2004 |
Olijslagers JE, Werkman TR, McCreary AC, Siarey R, Kruse CG, Wadman WJ. 5-HT2 receptors differentially modulate dopamine-mediated auto-inhibition in A9 and A10 midbrain areas of the rat. Neuropharmacology. 46: 504-10. PMID 14975674 DOI: 10.1016/J.Neuropharm.2003.10.003 |
0.08 |
|
| 1990 |
Long SK, Siarey RJ, Evans RH. Selectivity of CNQX for excitatory amino acid mediated responses European Journal of Pharmacology. 183: 1679-1680. DOI: 10.1016/0014-2999(90)91973-F |
0.077 |
|
| 2005 |
Olijslagers JE, Perlstein B, Werkman TR, McCreary AC, Siarey R, Kruse CG, Wadman WJ. The role of 5-HT(2A) receptor antagonism in amphetamine-induced inhibition of A10 dopamine neurons in vitro. European Journal of Pharmacology. 520: 77-85. PMID 16154561 DOI: 10.1016/J.Ejphar.2005.08.014 |
0.077 |
|
| 2002 |
Glennon J, McCreary AC, Ronken E, Siarey R, Hesselink MB, Feenstra R, Vliet BV, Long SK, Kruse CG. SLV313 is a dopamine D2 receptor antagonist and serotonin 5-HT1A receptor agonist: In vitro and in vivo neuropharmacology European Neuropsychopharmacology. 12: 277. DOI: 10.1016/S0924-977X(02)80381-9 |
0.056 |
|
| Hide low-probability matches. |